The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

Rapid Growth and Projections

• The viral and non-viral vector manufacturing market has seen substantial growth in recent years.
• Expected to reach $8.62 billion in 2024 at a CAGR of 19.5%.
• Projected to grow to $17.85 billion in 2028 at a CAGR of 20.0%.
• Growth driven by rising prevalence of genetic disorders, biotechnology advancements, and investments in gene therapy research.

The Rise Of Vector Therapies In Genetic Disorder Treatment

• Genetic disorders fuel market growth.
• Viral vectors deliver therapeutic genes, addressing genetic disorders.
• Non-viral vectors used in ex vivo gene therapy approaches.
• Increasing incidences of genetic disorders, like arthritis and diabetes, propel market expansion.

Read More On The Viral And Non-Viral Vector Manufacturing Market Report 2024 – https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

Merck KGaA’s Breakthrough In Viral And Non-Viral Solutions

• Technological advancements crucial for market players.
• Merck KGaA introduces VirusExpress 293 AAV Production Platform.
• Platform accelerates process development and clinical manufacture.
• Highlights the trend of innovative solutions to sustain market position.

Thermo Fisher’s Game-Changing Acquisition Of Henogen S.A.

• Thermo Fisher Scientific Inc. acquires Henogen S.A. for $874.5 million in January 2021.
• Aims to enhance capacity for cell and gene therapies and vaccines globally.
• Henogen S.A., a Belgium-based biomanufacturing company, offers viral vector manufacturing services.
• Acquisition underscores the importance of strategic acquisitions in expanding market presence.

Market Segmentation

• Segmented by Vector Type: Viral Vector, Non-Viral Vector.
• Segmented by Disease: Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases.
• Segmented by Application: Gene Therapy, Vaccinology, Cell Therapy, Other Applications.
• North America leads the viral and non-viral vector manufacturing market.

Conclusion: Navigating the Future The viral and non-viral vector manufacturing market is poised for significant growth, driven by advancements in biotechnology, rising demand for gene therapies, and increasing awareness of personalized medicine. Companies like Merck KGaA and Thermo Fisher Scientific Inc. are pioneering innovative solutions to meet evolving market needs. As the landscape continues to evolve, strategic investments and technological breakthroughs will play pivotal roles in shaping the future trajectory of the industry.

Request for A Sample Of The Global Viral And Non-Viral Vector Manufacturing Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=12570&type=smp